Vinflunine is a novel tubulin-targeted inhibitor indicated as a single agent for the treatment of bladder cancers after failure of prior platinum-based therapy. Its pharmacokinetics (PK) and pharmacodynamics (PD) have been independently characterized through several phase I and phase II studies. However, no global pharmacometric analysis had been conducted as yet.
Introduction
Vinflunine (VFL) ditartrate is a novel tubulin-targeted inhibitor belonging to the vinca alkaloid family. This bifluorinated semisynthetic molecule was selected for its particular mechanism of action and its higher level on in vivo antitumour activity compared with vinblastine or vinorelbine [1, 2] . Its clinical development started with three single agent pharmacokinetics Phase I studies of three different administration schedules: once every 3 weeks (q3w), weekly administration, and day 1/day 8 every 3 weeks. After completion of Phase I studies, 350 mg m -2 q3w was defined as the recommended Phase II dose [3] . However, after an interim analysis, the Phase II dose was reduced to 320 mg m -2 q3w to improve haematological tolerance. VFL disposition was found to be linear over the dose range from 30 to 400 mg m -2 [3] . Following intravenous (IV) administration, VFL is eliminated according to a multiexponential decay with a sharp decrease in blood concentrations during the 1 st h postinfusion then by a slower decrease thereafter, the terminal half-life of VFL being close to 40 h [3] . VFL is characterized by a high total blood clearance (>40 l h -1 ) and a large volume of distribution (2422 l) suggesting that the drug is extensively distributed into tissues. VFL is moderately bound to plasma proteins (40-78%), with a negligible binding to α1-glycoprotein and platelets [4] . As for the other vinca-alkaloids, VFL exhibits an important metabolism. It is metabolized by liver cytochromes (mainly CYP3A4 isoenzymes) into several inactive metabolites and by multiple esterases into 4-O-deacetylvinflunine, which is the predominant and only active metabolite of vinflunine [5] . The IV formulation of VFL (Javlor; Pierre Fabre Médica-ment, Boulogne, France) received a European Marketing Authorization as a single agent for the treatment of adult patients with advanced transitional cell carcinoma of the urothelium (bladder cancer) after failure of a prior platinumcontaining regimen at the dose of 320 mg m -2 administered as a 20-min infusion q3w. Dose limiting toxicities were myelosuppression (mainly neutropenia) which severity was related to drug exposure [6, 7] . With regards to nonhaematological adverse events (AEs), the most frequently observed (incidence >20%) were gastrointestinal symptoms (e.g. constipation, nausea, vomiting, stomatitis and abdominal pain), asthenia/fatigue, anorexia, alopecia, injection-site reactions and weight loss [8] . In general, all AEs with vinflunine were noncumulative and medically manageable. Several pharmacokinetic (PK) analyses from data obtained in Phase I or I/II studies were independently reported [3, [9] [10] [11] [12] [13] [14] [15] [16] ; however, a comprehensive clinical pharmacological evaluation (i.e. a pharmacometric approach) of VFL with data from all Phase I, I/II and II studies was missing. To address this gap, the present study was conducted to evaluate the PK of VFL using a population approach. This metaanalysis approach enabled to test the impact of various patients' characteristics (covariates) involved in the PK variability. Potential relationships between VFL PK and AEs were also investigated. Those analyses will help clinicians in guiding dose adjustments for individual patients.
Patients and methods

Clinical studies
Data were obtained from 18 clinical studies: eight Phase I, two Phase I/II, six Phase II and two Phase I studies in specific populations (details of the studies are in Table S1 ). All study protocols were approved by the institutional review board at each study centre and conducted in accordance with good clinical practice and the guiding principles of the Declaration of Helsinki. All study participants provided written informed consent before study entry.
VFL blood concentrations were measured by using a specific and sensitive HPLC method with UV detection. This method was fully validated for routine measurement of VFL with a lower limit of quantification of 2 ng ml -1 . The linearity was assessed from 2 ng ml -1 to 200 ng ml -1 . The coefficients of variation (both interday and intraday) and the absolute value of the bias, calculated from the quality controls, were lower than 6.9% and 5.8%, respectively.
Software
The population analyses [PK and PK/pharmacodynamic (PD)] were conducted via nonlinear mixed-effects modelling with NONMEM software, version 6.0 (ICON Development Solutions, Hanover, MD, USA) and results of both final analyses were confirmed using a newer NONMEM version (7.3.0). For PK analyses, FOCEI algorithm was used at all stages of model development, whereas FOCE was used for PK/PD analyses. All other statistical analyses were performed using SAS system, version 8.02 for PC (SAS Institute Inc. Cary, NC, USA).
Population PK model
All subjects with available dosing, actual sampling time, and evaluable concentration data were included in the population PK analysis. The structural model (covariate-free model) consisted of a linear four-compartment PK model, with a zero-order input as infusion rate (previously published in [17] ). The estimated PK parameters were: total body clearance (CL), volumes of distribution (V1, V2, V3 and V4) and three intercompartmental rate constants (K 21 , K 31 and K 41 ).
Occasions were analysed either as independent PK dataset or different occasions for a same patient. Several modifications on the random effect model were tested. All the models were evaluated on the basis of change in the objective function value (-2 × log-likelihood) and improvement in standard goodness-of-fit plots (i.e. population and individual predictions vs. observations and conditional weighted residual vs. population predictions and time), at each step of the model building.
Covariate analysis was performed on VFL clearance (CL) and volumes (V1-V4). In a first step, empirical Bayes estimates (posthoc parameters) were plotted against covariates, using scatterplots (for continuous variables) or boxplots (for categorical variables) to graphically assess the extent of correlation. In a second step, a general additive model analysis (using Xpose) was performed to choose the best and more parsimonious covariate model. Finally, based on previous results and clinical relevance, all pertinent covariates were included in the covariate-free model, thus obtaining the socalled full model. Then, all covariates were removed in turn (one at a time) from the full model and the increase in OFV (demonstrating a loss in the goodness of fit) was examined. An increase of OFV higher than 10.8 (P < 0.001) was considered to keep a covariate into the final model.
To qualify the final covariate model, a visual predictive check was conducted to allow visual comparison between distribution of simulated VFL concentrations and observed ones [18] . Bootstrap procedure was also performed (n = 200 estimations) on the final model.
Exposure-AE relationship
Two different analyses were performed, depending on the nature of the involved variables.
Population PK/PD modelling of neutrophil time course. A population PK/PD model based on a mechanistic approach was implemented to describe the time course of absolute neutrophil count after repeated VFL monotherapy administration. Briefly, the model consists of a series of compartments (i.e. five) that mimic neutropoiesis. One of the model parameters is the mean transit time (MTT), i.e. the time needed for cells to transit from the proliferation compartment to the circulating one. VFL concentration was assumed to reduce proliferation rate or induce cell loss in a linear fashion in the first compartment via a proportionality constant named slope, allowing delay between administration of VFL and the observed effect in the blood compartment (i.e. the last compartment). More information on the model may be found in [7] . The model evaluation was based on graphical diagnostic, goodness of fit plots, and precision of model parameters. Qualification of the model was done by visual predictive check, but also with comparison of the predicted and observed percent of patient experiencing grade 3/4 neutropenia following an administration of 320 mg m For the analysis of the grades of haematological AE and nonhaematological AE (where distributions of data were highly unbalanced between grades: no grade 4 and low incidence of grade 3) dichotomous logistic regression analysis based on a dichotomous outcome (response variable) was performed. The two categories were formed depending on the distribution of data among grades and also considering a clinically relevant cut-off. At least 10 observations were required for each category to perform a consistent analysis.
Simulations of exposure and risk of neutropenia in patients with normal or impaired renal function
To obtain VFL exposures, simulations based on the final covariate PK model were conducted 1000 times for three virtual patients. Doses were proposed in the summary of products characteristics (SPC) for patients with or without renal impairment. The three situations correspond to:
• Normal renal function (NRF): patient with creatinine clearance (CL cr ) = 61 ml min -1 , receiving 320 mg m -2 ,
• Moderate renal impairment (MRI): patient with CL cr = 41 ml min -1 , receiving 280 mg m -2 ,
• Severe renal impairment (SRI): patient with CL cr = 21 ml min Haematological toxicity for renal impaired patients was also evaluated according to different clinical situations. Absolute neutrophils time courses were simulated 500 times in four situations:
• MRI patient receiving 320 mg m -2 every month,
• MRI patient receiving 280 mg m -2 q3w,
• SRI patient receiving 280 mg m -2 every month,
• SRI patient receiving 250 mg m -2 q3w.
Percent of patients experiencing grade 3 or 4 neutropenia were then calculated at cycle 1 and cycle 2.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/ BPS Guide to PHARMACOLOGY [19] , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 [20] .
Results
PK
VFL blood concentration data were available for 372 patients on one or more occasions (656 PK profiles), leading to a total of 4980 VFL blood concentrations. In detail:
• For the three early Phase I studies, a rich-sampling blood collection was performed on the first VFL administration with an average of 15 time-points per patient (n = 79 patients). On the following administrations, a limited sampling strategy was performed with an average of five time-points per patient (n = 63 patients). The 79 early Phase I patients yielded a total of 233 PK profiles (79 with rich sampling and 154 with sparse sampling). A total of 1998 VFL blood samples was available.
• For the special population Phase I studies, a rich-sampling blood collection was performed with an average of 13 time-points per patient on Cycle 1 for the liver dysfunction study and on Cycle 1 and Cycle 2 for the renal impairment study. A total of 50 PK profiles from 39 patients was available. These studies yielded a total of 663 VFL blood samples.
• For the combination and Phase II studies, a limited sampling strategy was performed with an average of 7 timepoints per patient. Blood samples were collected during one or two cycles from individual patients in each study. A total of 254 patients and 373 PK profiles (n = 254 on cycle 1 or Day 1 and 119 on cycle 2 or Day 8) was available. The total number of VFL blood samples was 2319.
Demographics
The majority of subjects were male (55.6%). Fifty percent, 43.5% and 6.5% of the patients had an ECOG performance status of, respectively, 0, 1 or 2. The population consisted of 141 patients out of 372 with liver metastases. Most of the patients were treated as first line (41.1%) and 43% of them received VFL as part of a combination with either cisplatin, gemcitabine, carboplatin, PEGylated doxorubicin (PLDH), capecitabine, epirubicin or doxorubicin. Other patient characteristics are summarized in Table 1 . Studies involved in the exposure response relationships analysis were only the clinical trials where VFL was administered as a single agent. Thus, only 131 up to 210 patients out of the 372 patients were included, depending on the analyses performed.
PK analysis
After handling outlying and missing VFL PK data, 4154 timepoints were kept in the analysis.
Based on previous knowledge of VFL PK and results of the population PK analysis performed on Phase I data, a linear four-compartment model with zero order input as infusion rate was chosen as the starting structural model.
In a first step, all main parameters (CL, V, V2, V3, V4, K 21 , K 31 and K 41 ) as well as associated interindividual variabilities (IIVs) were estimated on the whole dataset. The interoccasion variability (IOV) was not included: each administration was considered as an independent PK dataset during the structural model development. IIVs on K 21 , K 31 and K 41 was not estimated (low IIV and/or very high relative standard error (> 80%)) when included in the model. Correlations between CL and V4, and between V and V2 were also added to the model. To estimate IOV, a second step consisted in running the same analysis without individualizing occasions. IOV was included only on CL. Indeed, despite high IOV on volumes (18-71%), it was not possible to obtain convergence of the runs.
Parameters of the final basic model with IOV on CL are summarized in Table 2 . Model parameters were estimated with a good precision; IIV on CL was low (28.2%), whereas it was larger on volumes, ranging from 42% (V3 and V4) to 82% (V2). Goodness of fit plots of the final basic model with IOV are shown in Figure 1 .
In a second step, the search for influential covariates was performed by using the final basic model without IOV (with each administration individualised). Based on covariates screening (graphical, mathematical or clinical relevance), the effect of the following covariates were individually tested:
• Covariates on CL: age, sex, weight, body surface area (BSA), body mass index, CL cr , total bilirubin, total serum proteins, alanine amino-transferase (ALAT), aspartate amino- The significant covariates related to CL, which were retained for « full » covariates model were: CL cr , BSA, age with cut-off at 65 years, chemonaïve status or not, and combination or not with epirubicin or PLDH. With regards to weight on volumes, its effect was kept only on V3 and V4 in the full covariates model. After a backward deletion step, the covariates retained in the final model were PLDH, CL cr and BSA on CL. Epirubicin cotreatment and previous chemotherapy effects were not found significant after deletion from the full model. Age (≤65 or >65 years) was statistically significant but was not retained in the final covariate model since 
Exposure-AE relationships analyses
Population PK/PD modelling of neutrophil time course. Data from 210 patients and 423 administrations coming from 5 Phase I and 6 Phase II studies were used. The most frequent dosing schedule was q3w, however several patients were treated on a weekly basis or on days 1 and 8 q3w. Overall, 1871 ANC values were available for the analysis. The population PK/PD models fully described the time course of neutrophils after vinflunine administration, as shown by standard goodness-of-fit plots (Figure 2 ). Observations vs. individual prediction graphs showed that there was no bias due to the structural model. None of the modifications tested in order to improve the model induced a significant change. Thus, only IOV on MTT and slope (i.e., difference for the same patient parameters between different chemotherapy cycles) was added; IOV was about 24% in both cases. The final model (Table 3) was then qualified using several tools. For instance, pharmacometrics specific tools such as visual predictive check, showing that most of the observed data lie into the interval of prediction (Figure 3) . Predictions of ANC values at Nadir (1.40 g l -1 ), onset (time to Nadir; 11.3 days) and duration of neutropenia (grade ≥ 3) (7.97 days) were consistent with the observed values (respectively, 1.38 g l -1 , 10.5 days, and 8.45 days).
With regards to percentage of patients experiencing a grade 3-4 neutropenia when treated at 320 mg m -2 q3w predictions and observations were, respectively, 47% and 49% at 1 st cycle and 46% and 43% for the first two cycles. These results strongly suggested that the PK/PD model was adequate to describe the grades of haematological toxicity, and especially for the severe grades of neutropenia.
Relationship between VFL AUC and grades of haematological and nonhaematological AEs. For haematological AEs, the analysed dataset was the same as the one used in the first cycle for the analysis of percent decrease of blood cells at nadir. There were 161 patients from three Phase I and six Phase II clinical trials with q3w schedule. For nonhaematological AE, the analysed dataset included 131 patients on Cycle 1 from two Phase I and six Phase II studies with a q3w schedule. Dichotomous logistic regression showed that the two only significant relationships between AUC and Vinflunine pharmacokinetics variability and exposure/toxicity relationship haematological AE were with grade of neutropenia and leucopenia. For an AUC of 14 000 ng ml -1 .h equivalent on average to a VFL dose of 320 mg m -2 , the estimated incidence of neutropenia and leucopenia were 47% and 32%, respectively, for grades ≥3. For a high AUC value of 23 000 ng ml Table 3 Final pharmacokinetic/pharmacodynamic (PK/PD) model for absolute neutrophil count time course after vinflunine administration respectively). However, no clinically significant difference was evidenced. With regards to grade 3 or 4 neutropenia in patients with renal insufficiency, as shown in Table 4 , delaying VFL administration by 1 week instead of decreasing the dose (i.e., every month instead of every 3 weeks) increase the risk at cycle 2. Thus, patients with renal insufficiency will benefit more of a dose reduction than a dose delay.
Discussion
Recently, several studies have evaluated efficacy and safety of vinflunine (VFL) in patients with relapsed urothelial cancer in clinical practice [21] [22] [23] [24] [25] [26] [27] [28] . Among them is the French CURVE study, the main objective of which was to retrospectively assess the efficacy and safety of VFL under routine conditions. Twenty centres participated in this study, enrolling 134 patients. They achieved a median OS of 8.18 months, which is consistent with the 6.9 median OS reported in the phase III controlled randomized clinical trial reported by Bellmunt et al. in 2009 [29] updated in 2013 [30] , after a median follow-up of 45.4 months.
Despite a less pronounced toxicity in the CURVE study as compared to the pivotal one, types of AEs were very similar: in the CURVE study, main grade 3 or 4 toxicities were neutropenia (17%), asthenia/fatigue (21%), anaemia (8%) and constipation (8%) with no toxic deaths. The goal of our study was to improve the understanding between VFL exposure (i.e., AUC) and toxicity, but also to understand which kind of patients were to experience toxicity (based on individual characteristics). To reach it, a clear evaluation of VFL pharmacokinetics and interindividual sources of variability was necessary.
Vinflunine disposition was best described by a fourexponential decrease in concentrations. The estimated parameters were CL, V, V2, V3, V4 and the rate constants K 21 , K 31 and K 41 . The model accurately described VFL blood profiles. The residual variability of the model was about 20%. VFL CL was found to be about 40 l h -1 (RSE = 1.4%), with inter-individual variability of 25% (RSE = 12%) and a very low IIV (IOV) of about 8% (RSE = 35%), meaning that elimination of VFL is highly constant over time. High IIV and IOV were estimated on volumes V and V2, which may be related to VFL PK profile (high and transient peak) and to the variations in VFL infusion rate. Because of the sharp decrease of concentrations occurring at the end of infusion, V and V2 estimates are very sensitive to variations or recording errors in sampling time, infusion durations or rates. The search for significant covariates was mainly focused on VFL CL, which is the parameter of interest (significant relationships were also 
Figure 3
Visual predictive checks of final pharmacokinetic/pharmacodynamic model following vinflunine administration of 320 mg m -2 once every found for both V3 and V4 with weight). As a demographic covariate, weight, body mass index and BSA were tested on VFL CL. Those three body size measurements explain part of VFL CL IIV; however, BSA, the one with the better improvement (in terms of OFV improvement and IIV decrease), was the only body size measurement kept in the final model. Current recommendations are to dose VFL based on patient BSA, which is supported by our study. In oncology, this is of particular interest, as BSA-based dosing is more and more questioned, due to poor link for some drugs between CL and BSA [31] . Moreover, VFL AUC was simulated for each dose level and renal impairment status and confirms similar exposures between patients with moderate and severe renal insufficiency. Exposure was 10% higher for patients with normal renal function, however, the clinical impact of this difference is limited. No difference in terms of toxicity was observed according to renal impairment, which is very similar to Isambert et al. [15] , where no difference in terms of exposure was observed. No effect of liver impairment could be evidenced on VFL disposition, as evidenced by the lack of relationship of VFL CL with either hepatic enzymes (ALP, ALAT, ASAT) or bilirubin. Moreover, the presence of hepatic metastases did not significantly alter VFL CL. This finding was in agreement with the lack of effect of liver impairment as previously established [32] . Neither the performance status nor the previous number of lines of chemotherapy (as well as chemonaïve vs. nonchemonaïve status) had an impact on VFL CL. Because of the large number and diversity of patients, this model can be applied to most patients treated with VFL. Moreover, as data are coming from multiple doses administration, the model can be applied in most clinical situations. To our knowledge, this is the first time that all those covariates were tested to explain VFL inter-individual variability. Of interest, even if the impact of covariates such as CL cr were known and already implemented in the SPC, our study demonstrates that elderly patients present the same exposure as younger ones. The relationships between VFL PK and haematological toxicity have been investigated through three separate analyses: percent decrease of blood cell counts at Nadir (results not presented), logistic regression and population PK/PD modelling. Very consistent results were obtained among the separate analyses. The semimechanistic population PK/PD model was developed from VFL monotherapy data and described the entire time course of neutrophils after different schedules of administration and after successive VFL administrations. System-related model parameters (i.e. base, MTT and γ) estimated from the current model were consistent with those reported on other anticancer drugs [7, 33, 34] . As for all similar models, the main limitation is the use of a linear drug effect instead of a more physiological one such as an E max model. However, due to the somewhat limited number of ANC per patient, estimating E max model parameters lead to computation difficulties. When compared to percent decrease of blood cell at nadir, the PK/PD modelling approach is more powerful and precise. Indeed, this model provided relevant clinical information regarding the degree, the onset and the duration of neutropenia and may be applied to other dosing schedule than q3w, whereas the percent of decrease approach only predicts the amplitude of neutrophil decrease for a given dosing schedule. Implemented in Nonmem, the PK/PD model could help clinicians in identifying patients at risk. For example, we have shown, based on simulations, that decreasing the dose to the one recommended in the SPC for renal impaired patients is the best way to limit incidence of grade 3 and 4 neutropenia as compared to delaying VFL administration. The model may also be used for simulation of neutropenia for alternative dosing schedule or dose, for example when VFL is to be clinically evaluated in combination with a non-neutropenic targeted therapy. Clinical trials will thus be more rationally conducted. Among the seven tested nonhaematological AEs, only fatigue was significantly (P < 0.0021) related to VFL AUC. There was no relationship with grades of constipation, nausea, vomiting, stomatitis, myalgia and abdominal pain/ cramps. The lack of correlation might be partly explained by the small sample size and by the low frequency of toxicity grades ≥ 3.
Conclusion
We propose for the first time a global comprehensive clinical pharmacological analysis for IV VFL. These analyses allow a better understanding of PK and toxicity variability and may help clinicians improve patient overall tolerance. The impact of BSA and renal function on VFL CL are reinforced and VFL AUC may be easily individually estimated with a simple formula. Implementing these models in a Bayesian tool may help drive dose adjustment.
